Contribution of IL-17 in Steroid Hyporesponsiveness in Obese Asthmatics Through Dysregulation of Glucocorticoid Receptors α and β

Saba Al Heialy, Mellissa Gaudet, Rakhee K Ramakrishnan, Andrea Mogas, Laila Salameh, Bassam Mahboub, Qutayba Hamid, Saba Al Heialy, Mellissa Gaudet, Rakhee K Ramakrishnan, Andrea Mogas, Laila Salameh, Bassam Mahboub, Qutayba Hamid

Abstract

Obesity is on the rise worldwide and is one of the most common comorbidities of asthma. The chronic inflammation seen in obesity is believed to contribute to this process. Asthma and obesity are associated with a poorer prognosis, more frequent exacerbations, and poor asthma control to standard controller medication. Difficult-to-treat asthma is associated with increased levels of Th17 cytokines which have been shown to play a central role in the upregulation of glucocorticoid receptor-beta (GR-β), a dominant-negative inhibitor of the classical GR-α. In this study, we studied the role of IL-17 cytokines in steroid hyporesponsiveness in obese asthmatics. We stimulated lean and obese adipocytes with IL-17A and IL-17F. Adipocytes obtained from obese patients cultured in vitro in the presence of IL-17A for 48 h showed a decrease in GRα/GRβ ratio as compared to adipocytes from lean subjects where GR-α/GR-β ratio was increased following IL-17A and IL-17F stimulation. At protein level, GR-β was increased in obese adipocytes with IL-17A and IL-17F stimulation. IL-8 and IL-6 expression was increased in IL-17-stimulated obese adipocytes. Pre-incubation with Dexamethasone (Dexa) led to a decrease in GR-α/GR-β ratio in obese adipocytes which was further affected by IL-17A whereas Dexa led to an increase in GR-α/GR-β ratio in lean adipocytes which was decreased in response to IL-17A. TGF-β mRNA expression was decreased in obese adipocytes in response to Th17 cytokines. We next sought to validate these findings in obese asthmatic patients. Serum obtained from obese asthmatic subjects showed a decrease in GRα/GRβ protein expression with an increase in IL-17F and IL-13 as compared to serum obtained from non-obese asthmatics. In conclusion, steroid hyporesponsiveness in obese asthmatic patients can be attributed to Th17 cytokines which are responsible for the dysregulation of the GRα/GRβ ratio and the inflammatory response.

Keywords: IL-17; asthma; glucocorticoid receptors; inflammation; obesity; steroid hyporesponsiveness.

Copyright © 2020 Al Heialy, Gaudet, Ramakrishnan, Mogas, Salameh, Mahboub and Hamid.

Figures

Figure 1
Figure 1
Stimulation with IL-17A & F and IL-17A alone induces changes in GR-α/GR-β mRNA ratio. Adipocytes from lean and obese subjects were stimulated with 100 ng/mL of IL-17A and IL-17F in combination or IL-17A alone for 48 h. Cells were collected and qRT-PCR analysis was performed in duplicate using TaqMan probes to assess GR-α and GR-β mRNA expression. One independent experiment performed per subject. n = 4 lean subjects, n = 3 obese subjects, One-Way ANOVA, Mean ± SE; *P < 0.05, **P < 0.01.
Figure 2
Figure 2
IL-17A & F and IL-17A alone induces changes in protein levels of GR-β. GR-α (A) and GR- β (B) protein expression in adipocytes from lean and obese subjects following 48 h stimulation with IL-17A&F combination or IL-17A alone (C) Ratio of GR-α/GR-β. n = 4 lean subjects, n = 3 obese subjects, One-way ANOVA, Mean ± SE; *P < 0.05, **P < 0.01, ***P < 0.001. Data is representative of three experiments.
Figure 3
Figure 3
Pre-treatment with Dexamethasone followed by IL-17A stimulation induces changes in GR-α/GR-β mRNA ratio. Adipocytes from lean and obese subjects were pre-treated with 500 ng/ml dexamethasone followed by a 48 h stimulation with 100 ng/ml of IL-17A. mRNA expression of GR-α and GR-β were measured by qRT-PCR in duplicates using TaqMan probes. One independent experiment preformed per subject: n = 4 lean subjects, n = 3 obese subjects, One-Way ANOVA, Mean ± SE; *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 4
Figure 4
Stimulation with IL-17A&F and IL-17A alone induces changes in mRNA expression of inflammatory mediators in adipocytes from lean and obese subjects. qRT-PCR analysis of detected mRNA expression of inflammatory markers: IL-8 (A), IL-6 (B), TGF-β (C), IL-1β (D) in mature adipocytes after 48 h stimulation with combination of IL-17A&F or IL-17A alone. n = 4 lean subjects, n = 3 obese subjects, One-way ANOVA, Mean ± SE; *P < 0.05, ***P < 0.001.
Figure 5
Figure 5
Stimulation with IL-17A&F and IL-17A alone induces changes in inflammatory cytokine profiles in adipocytes from lean and obese subjects. A multiplex assay was used to measure the levels of inflammatory cytokines: IL-8 (A), IL-6 (B), IL-5 (C), IL-4 (D), and IFN-γ (E) secreted by mature adipocytes after 48 h stimulation with IL-17A & F combination or IL-17A alone. One independent experiment preformed per subject. n = 4 lean subjects, n = 3 obese subjects, One-way ANOVA, Mean ± SE; *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 6
Figure 6
GR-α/GR-β ratio is decreased in serum of obese asthmatic subjects. Serum was obtained from lean (BMI 2), overweight (BMI < 30 kg/m2), obese (BMI < 35 kg/m2), and morbidly obese (BMI > 35 kg/m2) asthmatic subjects. (A,C) ELISA was used to assess protein levels of GR-α and GR-β. (B) Pearson correlation between BMI and GR-α/GR-β ratio. n = 43 non-obese subjects (n = 18 lean, n = 26 overweight), n = 57 obese subjects (n = 44 obese, n = 13 morbidly obese), Mean ± SE; *P < 0.05.
Figure 7
Figure 7
IL-17F production is increased in serum of obese asthmatics. Serum was obtained from lean (BMI 2), overweight (BMI < 30 kg/m2), obese (BMI < 35 kg/m2), and morbidly obese (BMI > 35 kg/m2) asthmatic subjects. (A–C) ELISA was used to assess protein levels of IL-17A, IL-17F, IL-13, respectively. (D) GR-α/GR-β ratio in subjects with high IL-17F and low IL-17F. n = 43 non-obese subjects, n = 57 obese subjects, Mean ± SE; *P < 0.05.

References

    1. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes. (2008) 32:1431–7. 10.1038/ijo.2008.102
    1. Khaodhiar L, McCowen KC, Blackburn GL. Obesity and its comorbid conditions. Clin Cornerstone. (1999) 2:17–31. 10.1016/S1098-3597(99)90002-9
    1. Mohanan S, Tapp H, McWilliams A, Dulin M. Obesity and asthma: pathophysiology and implications for diagnosis and management in primary care. Exp Biol Med (Maywood). (2014) 239:1531–40. 10.1177/1535370214525302
    1. Peters MC, McGrath KW, Hawkins GA, Hastie AT, Levy BD, Israel E, et al. . Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med. (2016) 4:574–84. 10.1016/S2213-2600(16)30048-0
    1. Straczkowski M, Kowalska I, Nikolajuk A, Dzienis-Straczkowska S, Szelachowska M, Kinalska I. Plasma interleukin 8 concentrations in obese subjects with impaired glucose tolerance. Cardiovasc Diabetol. (2003) 2:5. 10.1186/1475-2840-2-5
    1. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. (1994) 43:1271–8. 10.2337/diabetes.43.11.1271
    1. Nishimura S, Manabe I, Nagai R. Adipose tissue inflammation in obesity and metabolic syndrome. Discov Med. (2009) 8:55–60.
    1. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. (2001) 280:E745–51. 10.1152/ajpendo.2001.280.5.E745
    1. McArdle MA, Finucane OM, Connaughton RM, McMorrow AM, Roche HM. Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front Endocrinol. (2013) 4:52. 10.3389/fendo.2013.00052
    1. Ruddy MJ, Wong GC, Liu XK, Yamamoto H, Kasayama S, Kirkwood KL, et al. . Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem. (2004) 279:2559–67. 10.1074/jbc.M308809200
    1. Cosmi L, Liotta F, Maggi E, Romagnani S, Annunziato F. Th17 cells: new players in asthma pathogenesis. Allergy. (2011) 66:989–98. 10.1111/j.1398-9995.2011.02576.x
    1. Sumarac-Dumanovic M, Stevanovic D, Ljubic A, Jorga J, Simic M, Stamenkovic-Pejkovic D, et al. . Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes. (2009) 33:151–6. 10.1038/ijo.2008.216
    1. Ramakrishnan RK, Al Heialy S, Hamid Q. Role of IL-17 in asthma pathogenesis and its implications for the clinic. Expert Rev Respir Med. (2019) 13:1057–68. 10.1080/17476348.2019.1666002
    1. Al-Ramli W, Prefontaine D, Chouiali F, Martin JG, Olivenstein R, Lemiere C, et al. . T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol. (2009) 123:1185–7. 10.1016/j.jaci.2009.02.024
    1. Tashiro H, Shore SA. Obesity and severe asthma. Allergol Int. (2019) 68:135–42. 10.1016/j.alit.2018.10.004
    1. Mosen DM, Schatz M, Magid DJ, Camargo CA, Jr. The relationship between obesity and asthma severity and control in adults. J Allergy Clin Immunol. (2008) 122:507–11.e6. 10.1016/j.jaci.2008.06.024
    1. Forno E, Lescher R, Strunk R, Weiss S, Fuhlbrigge A, Celedon JC. Decreased response to inhaled steroids in overweight and obese asthmatic children. J Allergy Clin Immunol. (2011) 127:741–9. 10.1016/j.jaci.2010.12.010
    1. Goleva E, Covar R, Martin RJ, Leung DYM. Corticosteroid pharmacokinetic abnormalities in overweight and obese corticosteroid resistant asthmatics. J Allergy Clin Immunol Pract. (2016) 4:357–60.e2. 10.1016/j.jaip.2015.11.013
    1. Sobande PO, Kercsmar CM. Inhaled corticosteroids in asthma management. Respir Care. (2008) 53:625–33. discussion 33–4.
    1. Vazquez-Tello A, Halwani R, Hamid Q, Al-Muhsen S. Glucocorticoid receptor-beta up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells. J Clin Immunol. (2013) 33:466–78. 10.1007/s10875-012-9828-3
    1. van der Wiel E, Ten Hacken NH, van den Berge M, Timens W, Reddel HK, Postma DS. Eosinophilic inflammation in subjects with mild-to-moderate asthma with and without obesity: disparity between sputum and biopsies. Am J Respir Crit Care Med. (2014) 189:1281–4. 10.1164/rccm.201310-1841LE
    1. Martin RJ, Szefler SJ, King TS, Kraft M, Boushey HA, Chinchilli VM, et al. . The predicting response to inhaled corticosteroid efficacy (PRICE) trial. J Allergy Clin Immunol. (2007) 119:73–80. 10.1016/j.jaci.2006.10.035
    1. Tomlinson JE, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax. (2005) 60:282–7. 10.1136/thx.2004.033688
    1. Schatz M, Hsu JW, Zeiger RS, Chen W, Dorenbaum A, Chipps BE, et al. Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma. J Allergy Clin Immunol. (2014) 133:1549–56. 10.1016/j.jaci.2013.10.006
    1. Winer S, Paltser G, Chan Y, Tsui H, Engleman E, Winer D, et al. . Obesity predisposes to Th17 bias. Eur J Immunol. (2009) 39:2629–35. 10.1002/eji.200838893
    1. Ji Z, Wu S, Xu Y, Qi J, Su X, Shen L. Obesity promotes EAE through IL-6 and CCL-2-mediated T cells infiltration. Front Immunol. (2019) 10:1881. 10.3389/fimmu.2019.01881
    1. Han YY, Forno E, Brehm JM, Acosta-Pérez E, Alvarez M, Colón-Semidey A, et al. . Diet, interleukin-17, and childhood asthma in Puerto Ricans. Ann Allergy Asthma Immunol. (2015) 115:288–93.e1. 10.1016/j.anai.2015.07.020
    1. Hall SL, Baker T, Lajoie S, Richgels PK, Yang Y, McAlees JW, et al. . IL-17A enhances IL-13 activity by enhancing IL-13-induced signal transducer and activator of transcription 6 activation. J Allergy Clin Immunol. (2017) 139:462–71.e14. 10.1016/j.jaci.2016.04.037
    1. Kinyanjui MW, Shan J, Nakada EM, Qureshi ST, Fixman ED. Dose-dependent effects of IL-17 on IL-13-induced airway inflammatory responses and airway hyperresponsiveness. J Immunol. (2013) 190:3859–68. 10.4049/jimmunol.1200506
    1. Schmidt FM, Weschenfelder J, Sander C, Minkwitz J, Thormann J, Chittka T, et al. . Inflammatory cytokines in general and central obesity and modulating effects of physical activity. PLoS ONE. (2015) 10:e0121971. 10.1371/journal.pone.0121971
    1. Martínez-Reyes CP, Gómez-Arauz AY, Torres-Castro I, Manjarrez-Reyna AN, Palomera LF, Olivos-García A, et al. . Serum levels of interleukin-13 increase in subjects with insulin resistance but do not correlate with markers of low-grade systemic inflammation. J Diabetes Res. (2018) 2018:7209872. 10.1155/2018/7209872
    1. Mathews JA, Wurmbrand AP, Ribeiro L, Neto FL, Shore SA. Induction of IL-17A precedes development of airway hyperresponsiveness during diet-induced obesity and correlates with complement factor D. Front Immunol. (2014) 5:440. 10.3389/fimmu.2014.00440
    1. Sunadome H, Matsumoto H, Izuhara Y, Nagasaki T, Kanemitsu Y, Ishiyama Y, et al. . Correlation between eosinophil count, its genetic background and body mass index: the nagahama study. Allergol Int. (2020) 69:46–52. 10.1016/j.alit.2019.05.012
    1. Baffi CW, Winnica DE, Holguin F. Asthma and obesity: mechanisms and clinical implications. Asthma Res Pract. (2015) 1:1. 10.1186/s40733-015-0001-7
    1. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin immunol. (2005) 115:911–9; quiz 20. 10.1016/j.jaci.2005.02.023
    1. Thomas D, Apovian C. Macrophage functions in lean and obese adipose tissue. Metabolism. (2017) 72:120–43. 10.1016/j.metabol.2017.04.005
    1. Ouyang S, Liu C, Xiao J, Chen X, Lui AC, Li X. Targeting IL-17A/glucocorticoid synergy to CSF3 expression in neutrophilic airway diseases. JCI insight. (2020) 5:e132836. 10.1172/jci.insight.132836

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다